EichorEICHOR
Condition: Metastatic Or Locally Advanced Unresectable Solid Tumors Synced from ClinicalTrials.gov · August 08, 2026

Recruiting studies: Metastatic Or Locally Advanced Unresectable Solid Tumors

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerabili
Phase 1/Phase 2 · 10 location(s) · Lumara Bio Oncologics GmbH · NCT05706129A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
Phase 1 · 2 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT05470348A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment of Solid Tumors
Phase 1/Phase 2 · 39 location(s) · RemeGen Co., Ltd. · NCT07105215AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 3 location(s) · Avelos Therapeutics Inc. · NCT06911333Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients Wi
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06364410A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally Advanced Unresectable or Metastatic
Phase 1/Phase 2 · 31 location(s) · RemeGen Co., Ltd. · NCT06016062ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 6 location(s) · ABL Bio, Inc. · NCT07158918(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Phase 3 · 126 location(s) · Cogent Biosciences, Inc. · NCT05208047A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
Phase 1 · 20 location(s) · Astellas Pharma Inc · NCT07094204A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors
Phase 1/Phase 2 · 18 location(s) · RemeGen Co., Ltd. · NCT06038396A Phase 1 Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors
Phase 1 · 8 location(s) · NEOK Bio, Inc. · NCT07612176A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
Phase 2 · 19 location(s) · Elevar Therapeutics · NCT07359820Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
Phase 1 · 1 location(s) · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · NCT07589205A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works
Phase 1/Phase 2 · 11 location(s) · Regeneron Pharmaceuticals · NCT06413680A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
Phase 1 · 6 location(s) · Angiex, Inc. · NCT06440005Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Phase 1 · 5 location(s) · Regor Pharmaceuticals Inc. · NCT07524322Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The Co
Phase 2 · 482 location(s) · National Cancer Institute (NCI) · NCT05564377A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumor
Phase 1/Phase 2 · 10 location(s) · A2 Biotherapeutics Inc. · NCT06682793BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants W
Phase 1/Phase 2 · 32 location(s) · Marengo Therapeutics, Inc. · NCT05592626Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer
Phase 1/Phase 2 · 14 location(s) · Salubris Biotherapeutics Inc · NCT06667960IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors
Phase 1 · 5 location(s) · Innovent Biologics (Suzhou) Co. Ltd. · NCT06349408IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 3 location(s) · Innovent Biologics (Suzhou) Co. Ltd. · NCT06974812A Study of TAK-505 in Adults With Solid Tumors
Phase 1/Phase 2 · 15 location(s) · Takeda · NCT07436728A Study of TXN10128 in Subjects With Solid Tumors
Phase 1 · 6 location(s) · Txinno Bioscience Inc. · NCT05978492Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors
Phase 1 · 9 location(s) · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · NCT06963281A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Phase 1/Phase 2 · 7 location(s) · Astellas Pharma Global Development, Inc. · NCT07287995Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT05269381Study of IBI3005 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Phase 1 · 1 location(s) · Innovent Biologics (Suzhou) Co. Ltd. · NCT06418061SSGJ-705 Plus SSGJ-612 ± Chemotherapy in Advanced HER2-Expressing Solid Tumors
Phase 2 · 1 location(s) · Shenyang Sunshine Pharmaceutical Co., LTD. · NCT07646626
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.